| Literature DB >> 34234266 |
Hiroshi Kawame1, Akimune Fukushima2, Nobuo Fuse3, Fuji Nagami3, Yoichi Suzuki3, Mika Sakurai-Yageta3, Jun Yasuda3, Yumi Yamaguchi-Kabata3, Kengo Kinoshita3, Soichi Ogishima3, Takako Takai3, Shinichi Kuriyama3, Atsushi Hozawa3, Naoki Nakaya3, Tomohiro Nakamura3, Naoko Minegishi3, Junichi Sugawara3, Kichiya Suzuki3, Hiroaki Tomita3, Akira Uruno3, Tomoko Kobayashi3, Yayoi Aizawa3, Tomoharu Tokutomi2, Kayono Yamamoto4, Kinuko Ohneda5, Shigeo Kure3, Yoko Aoki6, Hideki Katagiri7, Yasushi Ishigaki2, Shojiro Sawada7, Makoto Sasaki2, Masayuki Yamamoto8.
Abstract
Certain large genome cohort studies attempt to return the individual genomic results to the participants; however, the implementation process and psychosocial impacts remain largely unknown. The Tohoku Medical Megabank Project has conducted large genome cohort studies of general residents. To implement the disclosure of individual genomic results, we extracted the potential challenges and obstacles. Major challenges include the determination of genes/disorders based on the current medical system in Japan, the storage of results, prevention of misunderstanding, and collaboration of medical professionals. To overcome these challenges, we plan to conduct multilayer pilot studies, which deal with different disorders/genes. We finally chose familial hypercholesterolemia (FH) as a target disease for the first pilot study. Of the 665 eligible candidates, 33.5% were interested in the pilot study and provided consent after an educational "genetics workshop" on the basic genetics and medical facts of FH. The genetics professionals disclosed the results to the participants. All positive participants were referred to medical care, and a serial questionnaire revealed no significant psychosocial distress after the disclosure. Return of genomic results to research participants was implemented using a well-prepared protocol. To further elucidate the impact of different disorders, we will perform multilayer pilot studies with different disorders, including actionable pharmacogenomics and hereditary tumor syndromes.Entities:
Mesh:
Year: 2021 PMID: 34234266 DOI: 10.1038/s10038-021-00952-8
Source DB: PubMed Journal: J Hum Genet ISSN: 1434-5161 Impact factor: 3.172